Teva Pharmaceutical Industries Market Forecasts & Analysis 2007-2012

Questions: Discounts, Updates etc.

Pages: 148

Price (Single): £1,999

Price (Departmental): £2,999

Price (Company): £4,999

Publication Date: 2007-05-17

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

Teva has a robust corporate strategy that should serve it well for years to come, driving strong growth and further innovation. Teva is therefore one of the most exciting and dynamic companies in the global pharmaceutical industry


In 2006, Teva Pharmaceutical Industries generated $8408m in net sales worldwide from both innovative branded and generic drugs, firmly establishing itself as a Top-20 international pharmaceutical company and leader in generics. That performance reflects rapid growth in recent years, as represented by a tripling in sales from $2519m in 2002. By 2010, total sales for Teva should reach $13.3bn.

With spectacular sales growth in recent quarters, Teva is expected to raise its profile even higher in the global pharmaceutical sector. Growth will be particularly evident in branded generics and innovative products. In particular, there will be significant developments in NCE development and international business, including further launches of innovative therapeutic molecules later this decade and early in the next. Stakeholders in the industry therefore cannot afford to ignore developments in Teva.

The purpose of this report is to examine the commercial prospects for Teva Pharmaceutical Industries in the global healthcare market. Teva is already competing well there, especially in key market segments and developing geographical markets. Its profile as a leading generics and innovation-driven pharmaceutical company will continue to rise. Teva Pharmaceutical Industries 2007-2012, critically examines that company through comprehensive research, market forecasting and qualitative analyses.

Teva's leading product is Copaxone, for multiple sclerosis, which generated $1414m during 2006. Other revenues are generated from a wide portfolio of generic pharmaceutical products and another innovative drug, Azilect, a treatment for Parkinson's disease. Teva also produces and markets active pharmaceutical ingredients (APIs) for the industry worldwide.

After its acquisition of generics rival -Ivax Corporation - in a deal finalised in early 2006, Teva achieved overall leadership of the global generics market. Teva clearly has a robust corporate strategy that should serve it well for years to come, driving strong growth and further innovation. Teva is therefore one of the most exciting and dynamic companies in the global pharmaceutical industry, visiongain believes. Consequently, participants in the global market should pay close attention to developments in Teva.

Teva Pharmaceutical Industries 2007-2012 examines that company critically, through comprehensive research and analysis. Importantly, visiongain discusses Teva in the context of the wider pharmaceutical market. This market-based research involved a detailed study of commercial documents, databases, company reports and relevant news. Importantly, visiongain applied techniques such as financial forecasting, SWOT analysis and qualitative projections.

In particular, Teva Pharmaceutical Industries 2007-2012 concentrates on the following essential aspects of that company:
- Detailed analysis of Teva's divisions and the performance of its products
- Sales forecasts for all Teva's divisions and the overall group
- Sales forecasts for Teva's innovative drugs - Copaxone and Azilect
- Discussions of issues affecting the relevant market segments
- Competitor analysis
- Drivers and opportunities for Teva
- Restraints and threats facing the company
- Discussions of corporate strategy in the context of the market
- Strategic alliances and licensing
- International operations
- Pipeline developments and their implications for the future

Leading generics companies such as Teva have established a new paradigm in the generics sector: that of developing innovative drugs. Other international generics companies are in a race to catch up with Teva, the world's leader in generics and a Top-20 pharmaceutical company in its own right. Teva has already achieved success with its leading innovative product Copaxone. Visiongain predicts that Teva's sales revenues will continue to rise strongly, as it harnesses opportunities in the expanding generics market and makes further progress as a global discovery-led company.

Table of Contents

  • Appendices
  • Appendix 1: Major Drugs Facing Patent Expiry in the US, 2004-2009
  • Appendix 2: About Visiongain
  • Appendix 3: Visiongain Report Evaluation Form

  • List of Tables
  • Table 2.1 Top 20 Global Pharmaceutical Companies, 2005
  • Table 2.2 Teva Net Sales and Income, 2002-2006
  • Table 2.3 Teva Subsidiaries, 2006
  • Table 2.4 Sales ($m) by Geographical Area, 2004-2006
  • Table 2.5 Sales ($m) by Business Division, 2004-2006
  • Table 2.6 Major Events in Teva USA's History
  • Table 3.1 Revenue Generation ($bn) by the World Pharmaceutical Industry, 2000-2006
  • Table 3.2 A SWOT Chart for Teva, 2007-2012
  • Table 3.3 Teva - Main Financials* ($m), 2005 and 2006
  • Table 3.4 Sales ($m) by Geographical Region, 2006
  • Table 3.5 Sales ($m) by Division, 2006
  • Table 3.6 Teva Sales ($m) by Division and Total Sales, 2006-2012
  • Table 3.7 Contribution (%) of Total Sales by Division, 2006 and 2012
  • Table 3.8 Teva Pharmaceutical Sales by Geographical Region and Leading National Markets, June 2005 to June 2006
  • Table 4.1 Pharmaceuticals Divisional Sales ($m), 2006-2012
  • Table 4.2 Copaxone and Azilect Sales ($m), 2006-2012
  • Table 4.3 Copaxone and Azilect Contribution to Sales (%), 2006-2012
  • Table 4.4 Copaxone Sales ($m), 2006-2012
  • Table 4.5 Sales ($m), 2006-2012
  • Table 4.6 Principal Therapeutic Products Manufactured by Teva, 2006
  • Table 4.7 Teva Pharmaceuticals: Top Five Therapeutic Classes, 2005-2006
  • Table 4.8 Pharmaceuticals: Leading International Products, 2005-2006
  • Table 5.1 Active Pharmaceutical Ingredients Divisional Sales ($m), 2006-2012
  • Table 6.1 R&D Investment by Teva, 2002-2006
  • Table 6.2 Antineoplastics/Immunomodulating Agents Pipeline
  • Table 6.3 Central Nervous System Agents
  • Table 6.4 Genitourinary System/Sex Hormones
  • Table 6.5 Respiratory System Agents
  • Table 6.6 Other Agents in Development
  • Table 7.1 Teva Sales ($m) by Division and Total Sales, 2006-2012

  • List of Figures
  • Figure 2.1 Teva Net Sales, 2002-2006
  • Figure 2.2 Teva Net Income, 2002-2006
  • Figure 2.3 Sales ($m) by Geographical Area, 2004-2006
  • Figure 2.4 Sales ($m) by Business Division, 2004-2006
  • Figure 2.5 Teva Employee Numbers, 2005 & 2006
  • Figure 3.1 Revenue Generation ($bn) by the World Pharmaceutical Industry, 2000-2006
  • Figure 3.2 Teva - Main Financials* ($m), 2005 and 2006
  • Figure 3.3 Sales ($m) by Geographical Region, 2006
  • Figure 3.4 Contribution (%) of Sales by Geographical Region, 2006
  • Figure 3.5 Sales ($m) by Division, 2006
  • Figure 3.6 Contribution (%) of Sales by Division, 2006
  • Figure 3.7 Teva Corporate Sales ($m), 2006-2012
  • Figure 3.8 Teva Sales ($m) by Division and Total Sales, 2006-2012
  • Figure 3.9 Sales ($m) by Division and Total Sales ($m), 2006 & 2012
  • Figure 3.10 Contribution (%) of Total Sales by Division, 2012
  • Figure 3.11 Teva Pharmaceutical Sales by Geographical Region and Leading Countries, June 2005 to June 2006
  • Figure 4.1 Pharmaceutical Division Sales ($m), 2006-2012
  • Figure 4.2 Copaxone and Azilect Sales ($m), 2006-2012
  • Figure 4.3 Copaxone and Azilect: Relative Contributions (%) to Teva Sales, 2006 and 2012
  • Figure 4.4 Copaxone Sales ($m), 2006-2012
  • Figure 4.5 Azilect Revenues ($m), 2006-2012
  • Figure 5.1 Active Pharmaceutical Ingredients Division Sales ($m), 2006-2012
  • Figure 6.1 R&D Investment by Teva, 2002-2006Figure 7.1 Teva - Main Financials* ($m), 2005 and 2006
  • Figure 7.2 Teva Sales ($m) by Division and Total Sales, 2006-2012

    • Other users found this report page using the following search terms: generic teva analysis pharmaceuticals pharmaceutical swot market sales pharma generic losartan

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.


    Refund and Cancellation Policy: The descriptions of the products and services sold on LeadDiscovery.co.uk are as complete and accurate as possible, and customers are encouraged to read all available information about a product before placing an order. Due to the nature of the information being sold, orders for reports cannot be canceled.